- Label RSS
Drug Label Info
Safety
- Report Adverse Events
- FDA Safety Recalls
- Presence in Breast Milk
Related Resources
- Medline Plus
- Clinical Trials
- PubMed
- All Citations
- Adverse Effects
- Therapeutic Use
- Pharmacology
- Clinical Trials
- Biochemical Data Summary
More Info For This Drug
- View Labeling Archives
- RxNorm
- Get Label RSS Feed
- View NDC Code(s)NEW!
- NDC Code(s): 46287-012-16
- Packager: CMP Pharma, Inc.
- Category: HUMAN PRESCRIPTION DRUG LABEL
- DEA Schedule: None
- Marketing Status: Abbreviated New Drug Application
Drug Label Information
Updated February 1, 2021
If you are a consumer or patient please visit this version.
- Download DRUG LABEL INFO: PDF XML
- Official Label (Printer Friendly)
View All Sections
- HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION safely and effectively. See full prescribing information for SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION
SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION, for oral or rectal use
Initial U.S. Approval: 1958SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION is a potassium binder indicated for the treatment of hyperkalemia (1).
Limitation of Use:
SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION should not be used an emergency treatment for life threatening hyperkalemia because of its delayed onset of action (1).
Oral: The average total daily adult dose of SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION is 15 g to 60 g, administered as a 15-g dose (four level teaspoons), one to four times daily (2.1).
Rectal: The average adult dose is 30 g to 50 g every six hours (2.1).
SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION is available as a light brown to brown, finely ground powder (3)
- Hypersensitivity to polystyrene sulfonate resins(4)
- Obstructive bowel disease (4)
- Neonates with reduced gut motility(4)
- Intestinal Necrosis: cases of intestinal necrosis and other serious gastrointestinal events have been reported (5.1).
- Electrolyte Disturbances: Severe hypokalemia can occur. (5.2).
- Fluid overload in patient sensitive to high sodium intake: Monitor patients who are sensitive to sodium intake for signs of fluid overload. (5.3).
- Risk of aspiration: Acute bronchitis or bronchopneumonia caused by inhalation of sodium polystyrene sulfonate particles has been reported. (5.4).
Adverse reactions reported include: anorexia, constipation, diarrhea, fecal impaction, gastrointestinal concretions (bezoars), ischemic colitis, nausea, vomiting (6).
To report SUSPECTED ADVERSE REACTIONS, contact CMP Pharma, Inc. at 1-844-321-1443 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
- Take other orally administered drugs at least 3 hours before or 3 hours after SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION (7.1).
- Cation-Donating Antacids: may reduce the resin's potassium exchange capability and increase risk of systemic alkalosis(7.2).
- Sorbitol: Concomitant use may contribute to the risk of intestinal necrosis and is not recommended (7.3).
See 17 for PATIENT COUNSELING INFORMATION.
Revised: 11/2017
- Table of Contents
2.1 General Information
2.2 Recommended Dosage
2.3 Preparation and Administration
5.1 Intestinal Necrosis
5.2 Electrolyte Disturbances
5.3 Fluid Overload in Patients Sensitive to High SodiumIntake
5.4 Risk of Aspiration
5.5 Binding to Other Orally Administered Medications
7.1 General Interactions
7.2 Cation-Donating Antacids
7.3 Sorbitol
8.1 Pregnancy
8.2 Lactation
8.4 Pediatric Use
12.1 Mechanism of Action
12.2 Pharmacodynamics
12.3 Pharmacokinetics
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
- *
- Sections or subsections omitted from the full prescribing information are not listed.
- 1 INDICATIONS AND USAGE
SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION is indicated for the treatment of hyperkalemia.
Limitation of Use:
SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see Clinical Pharmacology (12.2)].
- 2 DOSAGE AND ADMINISTRATION
2.1 General Information
Administer SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION at least 3 hours before or 3 hours after other oral medications. Patients with gastroparesis may require a 6 hour separation [see Warnings and Precautions (5.5) and Drug Interaction (7)]
2.2 Recommended Dosage
The intensity and duration of therapy depend upon the severity and resistance of hyperkalemia.
Oral
The average total daily adult dose of SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION is 15 g to 60 g, administered as a 15-g dose (four level teaspoons), one to four times daily.
Rectal
The average adult dose is 30 g to 50 g every six hours.
2.3 Preparation and Administration
Prepare suspension fresh and use within 24 hours.
Do not heat SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION as it could alter the exchange properties of the resin.
One level teaspoon contains approximately 3.5 g of SODIUM POLYSTYRENE
SULFONATE FOR SUSPENSION and 15 mEq of sodium.
Oral Suspension
Suspend each dose in a small quantity of water or syrup, approximately 3 to 4 mL of liquid per gram of resin. Administer with patient in an upright position [see Warnings and Precautions (5.4)].
Enema
After an initial cleansing enema, insert a soft, large size (French 28) rubber tube into the rectum for a distance of about 20 cm, with the tip well into the sigmoid colon, and tape in place.
Administer as a warm (body temperature) emulsion in 100 mL of aqueous vehicle and flush with 50 to 100 ml of fluid. A somewhat thicker suspension may be used, but do not form a paste.
Agitate the emulsion gently during administration. The resin should be retained for as long as possible and follow by a cleansing enema with a nonsodium containing solution. Ensure an adequate volume of cleansing solution (up to 2 liters) is utilized.
- 3 DOSAGE FORMS AND STRENGTHS
SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION is a light brown to brown, finely ground powder and is available in 454 g jars.
- 4 CONTRAINDICATIONS
SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION is contraindicated in patients with the following conditions:
- Hypersensitivity to polystyrene sulfonate resins
- Obstructive bowel disease
- Neonates with reduced gut motility
- 5 WARNINGS AND PRECAUTIONS
5.1 Intestinal Necrosis
Cases of intestinal necrosis, some fatal, and other serious gastrointestinal adverse events (bleeding, ischemic colitis, perforation) have been reported in association with SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION use. The majority of these cases reported the concomitant use of sorbitol. Risk factors for gastrointestinal adverse events were present in many of the cases including prematurity, history of intestinal disease or surgery, hypovolemia, and renal insufficiency and failure. Concomitant administration of sorbitol is not recommended.
- Use only in patients who have normal bowel function. Avoid use in patients who have not had a bowel movement post-surgery.
- Avoid use in patients who are at risk for developing constipation or impaction (including those with history of impaction, chronic constipation, inflammatory bowel disease, ischemic colitis, vascular intestinal atherosclerosis, previous bowel resection, or bowel obstruction). Discontinue use in patients who develop constipation.
5.2 Electrolyte Disturbances
Monitor serum potassium during therapy because severe hypokalemia may occur.
SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION is not totally selective for potassium, and small amounts of other cations such as magnesium and calcium can also be lost during treatment. Monitor calcium and magnesium in patients receiving SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION.
5.3 Fluid Overload in Patients Sensitive to High SodiumIntake
Each 15 g dose of SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION contains 1500 mg (60 mEq) of sodium. Monitor patients who are sensitive to sodium intake (heart failure, hypertension, edema) for signs of fluid overload.
Adjustment of other sources of sodium may be required.
5.4 Risk of Aspiration
Cases of acute bronchitis or bronchopneumonia caused by inhalation of sodium polystyrene sulfonate particles have been reported. Patients with impaired gag reflex, altered level of consciousness, or patients prone to regurgitation may be at increased risk. Administer SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION with the patient in an upright position.
5.5 Binding to Other Orally Administered Medications
SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION may bind orally administered medications, which could decrease their gastrointestinal absorption and lead to reduced efficacy. Administer other oral medications at least 3 hours before or 3 hours after SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION. Patients with gastroparesis may require a 6 hour separation. [see Dosage and Administration (2.1) and Drug Interactions (7)].
- 6 ADVERSE REACTIONS
The following adverse reactions are discussed elsewhere in the labeling:
- Intestinal Necrosis [see Warnings and Precautions (5.1)]
- Electrolyte Disturbances [see Warnings and Precautions (5.2, 5.3)]
- Aspiration [see Warnings and Precautions (5.4)]
The following adverse reactions have been identified during post-approval use of SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or establish a causal relationship to drug exposure.
Gastrointestinal: anorexia, constipation, diarrhea, fecal impaction, gastrointestinal concretions (bezoars), ischemic colitis, nausea, ulcerations, vomiting, gastric irritation, intestinal obstruction (due to concentration of aluminium hydroxide)
Metabolic: systemic alkalosis - 7 DRUG INTERACTIONS
7.1 General Interactions
No formal drug interaction studies have been conducted in humans.
SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION has the potential to bind other drugs. In in vitro binding studies, SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION was shown to significantly bind the oral medications (n=6) that were tested. Decreased absorption of lithium and thyroxine have also been reported with co-administration of SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION. Binding of SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION to other oral medications could cause decreased gastrointestinal absorption and loss of efficacy when taken close to the time SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION is administered. Administer SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION at least 3 hours before or 3 hours after other oral medications. Patients with gastroparesis may require a 6 hour separation. Monitor for clinical response and/or blood levels where possible.
7.2 Cation-Donating Antacids
The simultaneous oral administration of SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION with nonabsorbable cation-donating antacids and laxatives may reduce the resin's potassium exchange capability and increase the risk of systemic alkalosis.
7.3 Sorbitol
Sorbitol may contribute to the risk of intestinal necrosis [see Warnings and Precautions (5.1)] and concomitant use is not recommended.
- 8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Risk Summary
SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION is not absorbed systemically following oral or rectal administration and maternal use is not expected to result in fetal risk.
8.2 Lactation
Risk Summary
SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION is not absorbed systemically by the mother, so breastfeeding is not expected to result in risk to the infant.
8.4 Pediatric Use
Studies of safety and efficacy have not been conducted in pediatric patients.
In pediatric patients, as in adults, SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION is expected to bind potassium at the practical exchange ratio of 1mEq potassium per 1 gram of resin.
In neonates, SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION should not be given by the oral route. In both children and neonates, excessive dosage or inadequate dilution could result in impaction of the resin. Premature infants or low birth weight infants may have an increased risk for gastrointestinal adverse effects with SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION use [see Warnings and Precautions (5.4)].
- 10 OVERDOSAGE
Overdosage may result in electrolyte disturbances including hypokalemia, hypocalcemia, and hypomagnesemia. Appropriate measures should be taken to correct serum electrolytes (potassium, calcium, magnesium), and the resin should be removed from the alimentary tract by appropriate use of laxatives or enemas.
- 11 DESCRIPTION
SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION is a benzene, diethenyl-polymer, with ethenylbenzene, sulfonated, sodium salt and has the following structural formula:
The drug is a light brown to brown, finely ground, powdered form of sodium polystyrene sulfonate, a cation-exchange resin prepared in the sodium phase with an in vitro exchange capacity of approximately 3.1 mEq (in vivo approximately 1 mEq) of potassium per gram. The sodium content is approximately 100 mg (4.1 mEq) per gram of the drug. It can be administered orally or rectally as an enema.
One gram of SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION contains 4.1 mEq of sodium.
- 12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION is a non-absorbed, cation exchange polymer that contains a sodium counterion.
SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION increases fecal potassium excretion through binding of potassium in the lumen of the gastrointestinal tract. Binding of potassium reduces the concentration of free potassium in the gastrointestinal lumen, resulting in a reduction of serum potassium levels. The practical exchange ratio is 1 mEq K per 1 gram of resin.
As the resin passes along the intestine or is retained in the colon after administration by enema, the sodium ions are partially released and are replaced by potassium ions. This action occurs primarily in the large intestine, which excretes potassium ions to a greater degree than does the small intestine. The efficiency of this process is limited and unpredictably variable.
12.2 Pharmacodynamics
The effective lowering of serum potassium with SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION may take hours to days.
12.3 Pharmacokinetics
The in vivo efficiency of sodium-potassium exchange resins is approximately 33 percent; hence, about one third of the resin's actual sodium content is delivered to the body.
SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION is not absorbed systemically.
Drug Interactions
In vitro binding studies showed that SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION bound significantly to the following tested drugs – warfarin, metoprolol, phenytoin, furosemide, amlodipine and amoxicillin.
- 13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
Studies have not been performed.
- 16 HOW SUPPLIED/STORAGE ANDHANDLING
SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION is available as a light brown to brown, finely ground powder in jars of 1 pound (454 g), NDC 46287-012-16.
Store at 20° - 25° C (68° - 77° F); excursions permitted to 15° – 30° C (59° – 86° F) [see USP Controlled Room Temperature]
- 17 PATIENT COUNSELINGINFORMATION
Drug Interactions
Advise patients who are taking other oral medication to separate the dosing of SODIUM POLYSTYRENE SULFONATE FOR SUSPENSION by at least 3 hours (before or after) [see Dosage and Administration (2.1), Warnings and Precautions (5.5), and Drug Interactions (7.1)]
- SPL UNCLASSIFIED SECTION
Rx Only
Manufactured by:
CMP Pharma, Inc.
Farmville, NC 27828
Copyright©2017. CMP Pharma Inc. All rights reserved.3018
Revised 11/2017 - PRINCIPAL DISPLAY PANEL - 454 g Jar Label
NDC 46287-012-16
454 gSodium Polystyrene
Sulfonate for SuspensionUSUAL DOSAGE: 15 g (approximately 4 level teaspoonfuls)
one to four times daily in water. For rectal use, see complete
instructions in package insert The effect must be carefully
controlled by frequent serum potassium determinations
within each 24 hour period Sodium content approximately
60 mEq per 15 g.SEE PACKAGE INSERT FOR COMPLETE INSTRUCTIONS.
Suspension should be freshly prepared and not stored beyond
24 hours.Dispense in a tight, light resistant container.
Store at 20°-25°C (68°-77°F); excursions permitted to
15°-30°C (59°-86°F). [See USP Controlled Room
Temperature].
GTIN: 00346287012160Rx Only
3047
R1017PHARMA
Farmville, NC 27828 - INGREDIENTS AND APPEARANCE
SODIUM POLYSTYRENE SULFONATE
sodium polystyrene sulfonate powder, for suspensionProduct Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:46287-012 Route of Administration ORAL, RECTAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength SODIUM POLYSTYRENE SULFONATE (UNII: 1699G8679Z) (POLYSTYRENE SULFONIC ACID - UNII:70KO0R01RY) SODIUM POLYSTYRENE SULFONATE 1g in1g Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:46287-012-16 454 g in 1 JAR; Type 0: Not a Combination Product 01/19/1989 Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA089910 01/19/1989 Labeler -CMP Pharma, Inc.(005224175)
Establishment Name Address ID/FEI Business Operations CMP Pharma, Inc. 005224175 MANUFACTURE(46287-012) , PACK(46287-012) , LABEL(46287-012) , ANALYSIS(46287-012)
View All Sections
Find additional resources
(also available in the left menu)
Safety
Report Adverse Events, FDA Safety Recalls, Presence in Breast Milk
Related Resources
Medline Plus, Clinical Trials, PubMed, Biochemical Data Summary
More Info on this Drug
View Labeling Archives, RxNorm, Get Label RSS Feed, View NDC Code(s)NEW!
View Labeling Archives for this drug
SODIUM POLYSTYRENE SULFONATE powder, for suspension
Number of versions: 6
Published Date (What is this?) | Version | Files |
---|---|---|
Feb 2, 2021 | 6 (current) | download |
Dec 24, 2020 | 5 | download |
Mar 9, 2018 | 4 | download |
Mar 7, 2017 | 3 | download |
Oct 16, 2012 | 2 | download |
Sep 5, 2012 | 1 | download |
RxNorm
SODIUM POLYSTYRENE SULFONATE powder, for suspension
RxCUI | RxNorm NAME | RxTTY | |
---|---|---|---|
1 | 2101899 | sodium polystyrene sulfonate 15 GM Powder for Suspension | PSN |
2 | 2101899 | sodium polystyrene sulfonate 15000 MG Powder for Oral Suspension | SCD |
3 | 2101899 | sodium polystyrene sulfonate 15 to 60 GM Powder for Oral Suspension | SY |
4 | 2101899 | sodium polystyrene sulfonate 30 to 50 GM Powder for Rectal Suspension | SY |
5 | 2101899 | sodium polystyrene sulfonate 4.1 MEQ in 1 GM Powder for Oral Suspension | SY |
Get Label RSS Feed for this Drug
SODIUM POLYSTYRENE SULFONATE powder, for suspension
To receive this label RSS feed
Copy the URL below and paste it into your RSS Reader application.
https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=2017bfbe-cda8-46f1-b4f1-9c086c3249a9
To receive all DailyMed Updates for the last seven days
Copy the URL below and paste it into your RSS Reader application.
https://dailymed.nlm.nih.gov/dailymed/rss.cfm
What will I get with the DailyMed RSS feed?
DailyMed will deliver notification of updates and additions to Drug Label information currently shown on this site through its RSS feed.
DailyMed will deliver this notification to your desktop, Web browser, or e-mail depending on the RSS Reader you select to use. To view updated drug label links, paste the RSS feed address (URL) shown below into a RSS reader, or use a browser which supports RSS feeds, such as Safari for Mac OS X.
How to discontinue the RSS feed
If you no longer wish to have this DailyMed RSS service, simply delete the copied URL from your RSS Reader.
Why is DailyMed no longer displaying pill images on the Search Results and Drug Info pages?
Due to inconsistencies between the drug labels on DailyMed and the pill images provided by RxImage, we no longer display the RxImage pill images associated with drug labels.
We anticipate reposting the images once we are able identify and filter out images that do not match the information provided in the drug labels.
NDC Codes
SODIUM POLYSTYRENE SULFONATE powder, for suspension
If this SPL contains inactivated NDCs listed by the FDA initiated compliance action, they will be specified as such.
NDC | |
---|---|
1 | 46287-012-16 |